Capital One Financial Comments on Amphastar Pharmaceuticals, Inc.’s Q1 2024 Earnings (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) – Research analysts at Capital One Financial issued their Q1 2024 earnings per share estimates for Amphastar Pharmaceuticals in a report released on Wednesday, April 17th. Capital One Financial analyst T. Chiang expects that the company will post earnings of $0.72 per share for the quarter. The consensus estimate for Amphastar Pharmaceuticals’ current full-year earnings is $3.42 per share. Capital One Financial also issued estimates for Amphastar Pharmaceuticals’ Q2 2024 earnings at $0.72 EPS, Q3 2024 earnings at $1.01 EPS and Q4 2024 earnings at $1.03 EPS.

Other research analysts have also issued research reports about the stock. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, April 10th. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Finally, JPMorgan Chase & Co. initiated coverage on Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price target on the stock. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $66.00.

Amphastar Pharmaceuticals Trading Down 3.5 %

Shares of Amphastar Pharmaceuticals stock opened at $38.65 on Thursday. The company’s fifty day moving average price is $46.59 and its two-hundred day moving average price is $51.23. The firm has a market capitalization of $1.89 billion, a PE ratio of 14.98, a price-to-earnings-growth ratio of 0.98 and a beta of 0.84. Amphastar Pharmaceuticals has a 52-week low of $35.62 and a 52-week high of $67.66. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.17 and a quick ratio of 1.70.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, February 28th. The company reported $0.81 EPS for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). The firm had revenue of $178.11 million during the quarter, compared to analyst estimates of $174.90 million. Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in shares of Amphastar Pharmaceuticals by 1.1% in the 3rd quarter. BlackRock Inc. now owns 7,147,813 shares of the company’s stock valued at $200,854,000 after purchasing an additional 75,616 shares during the period. Federated Hermes Inc. lifted its stake in Amphastar Pharmaceuticals by 0.7% in the 1st quarter. Federated Hermes Inc. now owns 3,487,430 shares of the company’s stock valued at $125,199,000 after acquiring an additional 23,095 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Amphastar Pharmaceuticals by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 2,815,596 shares of the company’s stock worth $174,145,000 after acquiring an additional 48,203 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Amphastar Pharmaceuticals by 2.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,917,571 shares of the company’s stock valued at $71,909,000 after buying an additional 51,027 shares during the last quarter. Finally, State Street Corp increased its position in shares of Amphastar Pharmaceuticals by 16.6% in the second quarter. State Street Corp now owns 1,540,846 shares of the company’s stock valued at $53,606,000 after acquiring an additional 218,895 shares during the last quarter. 65.09% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Michael A. Zasloff sold 12,500 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total value of $589,750.00. Following the sale, the director now directly owns 21,326 shares in the company, valued at approximately $1,006,160.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the completion of the sale, the director now directly owns 21,326 shares in the company, valued at $1,006,160.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Floyd F. Petersen sold 500 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $53.10, for a total value of $26,550.00. Following the transaction, the director now owns 80,333 shares in the company, valued at approximately $4,265,682.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,000 shares of company stock valued at $660,860. 28.40% of the stock is currently owned by insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.